Most medicines in development today target diseases affecting large sections of the global population, but we are beginning to see a rise in the interest of developing ”orphan drugs,” or pharmaceutical agents intended to treat rare diseases.
Download our white paper for insights on:
- Challenges in orphan drug development
- Considerations associated with the expedited development of orphan drugs
- How to optimally position your organization to address relevant constraints
